Dr. Pierre-Emmanuel Gerard
Chief Executive Officer and Founder
Dr. Gerard founded BIOMUNEX Pharmaceuticals in 2014 in Paris with 2 co-founders, Prof. Jean-Pierre Mach, a pioneer in immunotherapy research from University of Lausanne (CH), and Geoffroy de Ribains, now CEO at Step Pharma, and previously venture capital investor.
Prior to founding BIOMUNEX, Dr. Gerard acted as a Partner in international strategy consulting companies for 6 years (AEC Partners, IMS Health). In this position, he advised managing directors and managers from leading pharma and biotech companies on key strategic decisions. Dr. Gerard also created two successful healthcare companies. Prior to that, Dr. Gerard was a senior corporate executive in the pharma/biotech industry for 13 years (Pierre Fabre, Servier). As an Advisor to the President (ie: Pierre Fabre Group), Dr. Gerard was in charge of reorganizing R&D and biotech; he directed clinical development strategy for several products. He then acted as a Managing Director of a subsidiary in Italy. Dr. Gerard began his career in business development (eg. creation of Biogaran, a generics leader in France); subsequently he served as a Managing Director of a biotech incubator and seed fund (Genopole, Evry). Dr. Gerard is a Medical Doctor (Nice, FR; Cambridge, UK) and holds an MBA from HEC Business School (Paris, FR).
Dr. Eugene Zhukovsky
Chief Scientific Officer
Dr. Zhukovsky has more than 25 years professional experience in the field of biotherapeutics research and development. Prior to joining BIOMUNEX as Chief Scientific Officer in January 2015, Dr. Zhukovsky was Chief Scientific Officer of Affimed Therapeutics since 2011. Prior to that, he was a Senior Research Fellow in the Biotherapeutics Department at Boehringer Ingelheim Pharmaceuticals, Inc. Prior to that, Dr. Zhukovsky was an Associate Director at Xencor, Inc. where he led translational research efforts resulting in several therapeutic candidates targeting malignant and normal B cells. Dr. Zhukovsky began his professional career employing phage display technology at Neurex Corporation (now Perrigo Company). Dr. Zhukovsky then moved to Lynx Therapeutics (now Illumina, Inc.) to work on the development of genomics technologies before returning to protein/antibody engineering and biotherapeutics development at Xencor, Inc.Dr. Zhukovsky received a PhD in biochemistry from Brandeis University (Waltham, USA) and was a postdoctoral fellow at Genentech. .
Dr. Olivier Léger
Antibody Engineering Expert
Dr. Léger is an experienced antibody engineer with over 20 years of accomplishments in research, research management, project management for discovery project teams, intellectual property, lead discovery and preclinical development in biotech and pharma companies. For these last 15 years, Dr. Léger served as Antibody engineering director in Pierre Fabre, NovImmune, as well as Merck Serono. Dr. Léger is a co-inventor of Natalizumab, a humanized monoclonal antibody, marketed as Tysabri® for the treatment of multiple sclerosis, is a co-inventor in 18 patents, co-author of 17 scientific publications and book chapters. Previously Olivier was a scientist in MRC Collaborative Centre (London, UK). Dr. Olivier Léger holds a PhD in Molecular Immunology, from the University of London (UK), at Institute of Cancer research (Sutton, UK).
BIOMUNEX is currently building a strong scientific research and management team to execute its ambitious development plan.
BOARD OF SCIENTIFIC AND STRATEGIC ADVISORS
BIOMUNEX ’ Key Scientific and Strategic Advisors are international key opinion leaders in their field. They will play an instrumental role as we advance oncology programs into pre-clinical and clinical development
Dr. Sebastian Amigorena
Dr. Sebastian Amigorena, is a research director at CNRS and director of the INSERM ‘Immunity and Cancer’ Unit at the Institut Curie in Paris. His team focuses on leveraging the responses to tumors by the immune system in order to identify novel paradigms in oncology, which can be employed for immunotherapy in cancer patients. A renowned key opinion leader in immuno-oncology, Dr. Amigorena obtained his PhD in biochemistry and immunology from the University of Paris VII and performed a post-doctoral fellowship at the cell biology department of the Yale University School of Medicine. Dr. Amigorena contributes to the editorial and review boards of numerous prestigious peer-reviewed scientific journals. He has published more than 150 articles in immunology, in particular with a focus on the biology of dendritic cells and immunomodulation. He is or has been a member of several scientific advisory boards (ANR, INSERM, Fondation Schueller-Bettencourt, ERC, etc) and scientific societies (including the French Academy of Science). Dr Amigorena has received numerous national and international distinction awards.
Dr. Dragan Grabulovski
Dr. Dragan Grabulovski is an advisor in pharmaceutical biotechnology at Grabulovski Consulting Services (CH). He was previously chief scientific officer and co-founder of Covagen AG, a Swiss biotech company acquired in 2014 by Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson. As Covagen’s CSO, he was responsible for developing and overseeing the execution of the overall strategy for research and development. He was a main inventor of the Fynomer technology, established a portfolio of novel bispecific FynomAb product candidates and managed the internal and collaboration pipeline. As a member of Covagen’s executive management team, Dr. Grabulovski was instrumental in Covagen’s trade sale to Johnson & Johnson, and in the closing of Covagen’s CHF 45M ($44.5M) Series B round in 2014 with the participation of renowned investors such as GIMV, Edmond de Rothschild Investment Partners, Novartis Venture Fund and other prestigious funds. Dr. Grabulovski received his master’s degree in pharmaceutical sciences and Doctor of Sciences from ETH Zurich (CH). He is a co-author of several peer-reviewed articles, reviews, book chapters, poster abstracts, patent applications and granted patents.
Dr. Jean-Marc Herbert
Dr. Jean-Marc Herbert has more than 30 years of industrial experience in the pharmaceutical research and development at international management positions. In 2007-09, he was Senior VP, in charge of Discovery at Sanofi-Aventis Research. In 2009-15, he was leading a multinational group at Sanofi, based in Europe, US and China called « Early to Candidate » at the interface between academia and Pharma R&D. Prior to that, he worked as International Director of a Research Department for Sanofi Recherche. During his career, he also played significant roles in the discovery and development of marketed drugs, such as Plavix® and Arixtra®). Jean-Marc Herbert received his Ph.D. in cellular and molecular biology from the University of Clermont-Ferrand, France. He also did a PhD in cellular biology and biochemistry at the Clinical Research Center, London, UK. He has authored more than 400 papers in various fields, including cancer, inflammation, thrombosis, vascular biology, and cardiology. Dr. Herbert today is the President of ARKELY-Consulting, a company consulting in Translational Research for drug discovery & development, with particular expertise in Oncology, Immune and Inflammatory indications, and other therapeutic domains. ARKELY-Consulting advises clients in the pharma-biotech industry, capital investment & premier consulting firms.